Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.59 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.54 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.47 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | TDO2 | P48775 | 2/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.39 |
| ▸ | AKT2 | P31751 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10684546 | 0.97 | HTR2A (0.56) | HTR2ATAAR1CHRNB2CHRNA4GABBR2 | |
| SCHEMBL3910286 | 0.93 | HTR2A (0.73) | HTR2ATAAR1CHRNB2CHRNA4GABBR2 | |
| Hydrochloric Acid SCHEMBL3891276 | 0.91 | HTR2A (0.70) | HTR2ATAAR1CHRNB2CHRNA4IDO1 | |
| SCHEMBL4618800 | 0.80 | HRH1 (0.62) | HTR2ATAAR1GABBR2GABBR1IDO1 | |
| SCHEMBL11085032 | 0.79 | GABBR2 (0.62) | TAAR1GABBR2GABBR1IDO1TDO2 | |
| SCHEMBL16462055 | 0.78 | P2RX7 (0.50) | HTR2ATAAR1CHRNB2CHRNA4CYP19A1 | |
| Hydrochloric Acid SCHEMBL9662256 | 0.78 | HRH1 (0.60) | HTR2ATAAR1IDO1TDO2LOXL2 | |
| SCHEMBL18466458 | 0.77 | GABBR2 (0.46) | TAAR1GABBR2GABBR1IDO1TDO2 | |
| SCHEMBL5502468 | 0.77 | GABBR2 (0.46) | TAAR1GABBR2GABBR1IDO1TDO2 | |
| SCHEMBL6085867 | 0.77 | LOXL2 (0.50) | TAAR1GABBR2GABBR1IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873702-B2 | Heterocyclic compounds as biogenic amine transport modulators | SOUTHERN RESEARCH INSTITUTE (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3226867-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | Ananthan, Subramaniam (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20160159809-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | SOUTHERN RESEARCH INSTITUTE | 2016-06-09 | — | — | US | disclosed |
| WO-2016090296-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | ANANTHAN SUBRAMANIAM (US) | 2016-06-09 | — | — | WO | disclosed |
| US-7737167-B2 | 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels | NEUROSEARCH A/S (DK) | 2010-06-15 | — | — | US | disclosed |
| EP-1776348-B1 | 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | NEUROSEARCH AS (DK) | 2008-05-28 | — | — | EP | disclosed |
| US-7268166-B2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268166-B2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-20070197618-A1 | Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels | NEUROSEARCH A/S (DK) | 2007-08-23 | — | — | US | disclosed |
| EP-1776348-A2 | 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 2007-04-25 | — | — | EP | disclosed |
| EP-1069132-B1 | Bicyclic derivatives of amino-pyrazinones, process of preparation and pharmaceutical compositions comprising them | SERVIER LAB (FR) | 2003-10-01 | — | — | EP | disclosed |
| US-20030181490-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2003-09-25 | — | — | US | disclosed |
| US-20030027847-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-06 | — | — | US | disclosed |
| EP-1069132-A1 | Bicyclic derivatives of amino-pyrazinones, process of preparation and pharmaceutical compositions comprising them | ADIR ET COMPAGNIE (FR) | 2001-01-17 | — | — | EP | disclosed |
| US-5225411-A | Triazines | ADIR ET COMPAGNIE (FR) | 1993-07-06 | — | — | US | disclosed |
| EP-0139358-B1 | N6-SUBSTITUTED DIARYLALKYL ADENOSINES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | WARNER-LAMBERT COMPANY (US) | 1988-11-09 | — | — | EP | disclosed |
| EP-0251339-A2 | N6- substituted diarylalkyl adenosines, processes for their production and pharmaceutical compositions comprising the same | WARNER-LAMBERT COMPANY (US) | 1988-01-07 | — | — | EP | disclosed |
| US-4657898-A | CARDIOVACULAR AND PSYCHOLOGICAL DISORDERS, ANALGESICS, OR SEDATIVES | WARNER-LAMBERT COMPANY (US) | 1987-04-14 | — | — | US | disclosed |
| US-4657897-A | N6 -substituted adenosines for treating pain | WARNER-LAMBERT COMPANY (US) | 1987-04-14 | — | — | US | disclosed |
| EP-0139358-A2 | N6-substituted diarylalkyl adenosines, processes for their production and pharmaceutical compositions comprising the same | WARNER-LAMBERT COMPANY (US) | 1985-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181490-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | HTR2A 3482/4885TAAR1 2149/4885CHRNB2 3468/4885 |
| US-20160159809-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | SLC18A2, SLC6A2, SLC6A3 | HTR2A 22/4885TAAR1 11/4885CHRNB2 126/4885 |
| US-20070197618-A1 | Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels | KCNN2, KCNN1, KCNN3 | HTR2A 1181/4885TAAR1 3581/4885CHRNB2 427/4885 |
| US-20030027847-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | HTR2A 3482/4885TAAR1 2149/4885CHRNB2 3468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.